News | June 03, 2022
CMP Pharma announces calcium channel blocker ‘Norliqva’ availability
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Auld is a seasoned Financial Executive with over 30 years of relevant experience
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
For the third straight year, Lumenis wins an award recognizing outstanding medical companies and technologies
Subscribe To Our Newsletter & Stay Updated
